Obesity and Control : Open Access

Editor In Chief: Jaime Ruiz-Tovar PoloPhD

Associated Professor
Departmentof Surgery and Pathology
Miguel Hern�ndez University of Elche
Address:Spain
Biography

Jaime Ruiz-Tovar, MD, PhD, is General and Digestive Surgeon at General University Hospital Elche (Spain), where he is specialized in bariatric surgery. Associated Professor of Surgery at Universidad Miguel Hern�ndez. Secretary of the Surgical Infections Section of the Spanish Surgical Society. He actually leads several investigational projects focused on bariatric surgery and surgical infections.

Research Interests
Publications
Scientific Activities

Jerzy JankunPhD

Professor
Department of Urology
Health Science Campus The University of Toledo
Address:USA
Biography

Dr. Jerzy Jankun is the founding Director of Urology Research Center and Professor at Department of Urology, at Health Science Campus of University of Toledo. URC scientific research interest concentrates on proteolysis and different cancers and other diseases. Inhibition of photolytic activity reduce cancer induced angiogenesis and consequently tumor growth. Additionally inhibitors of proteolysis can reduce cancer spread. Special interest includes modified proteins to be used in therapy. That includes plasminogen activator type 1 with very long half-life (VLHL PAI-1) and modified human lipoxygenase. In the past laboratory explored photodynamic therapy to eradicate prostate and other cancers using small molecular weight photosensitizers and sensitizers conjugated with antibodies in targeted photodynamic cancer therapy (PDT).

Research Interests

Special interest includes modified proteins to be used in therapy. That includes plasminogen activator type 1 with very long half-life (VLHL PAI-1) and modified human lipoxygenase. In the past laboratory explored photodynamic therapy to eradicate prostate and other cancers using small molecular weight photosensitizers and sensitizers conjugated with antibodies in targeted photodynamic cancer therapy (PDT).

Publications

1. Jankun J. A Conductometric Methods of Particle Diameter Determination of Food Powders. Biuletyn IZ CLPKS, 3, 53-57, 1975 (in Polish).

2. Jankun J. Review of the Apparatus for Measurement of Relative Humidity of Air and Some Solid Materials. Biuletyn I Z and CLPKS, 1, 9-31, 1976 (in Polish).

3. Pazola Z. Cieslak J. Jankun J. Method of Producing a Sweetener for Diabetics and Low-calorie Sugar. Prace Instytutow i Laboratoriow Badawczych Przemyslu Spozywczego, 27, 69-72, 1977 (in Polish).

4. Jankun J. A Reflective Device for Wetting Time Estimation of Food Powders. Committee of Polish Academy of Sciences, VIII Symposium, Poznan 15-17 Feb. 1977, Proceedings of Polish Academy of Science, 1977 (in Polish).

5. Jankun J. Pazola Z. Cieslak J. Determination of Physical Properties of Food Products. Committee of Technology and Chemistry of Food, Polish Academy of Sciences, VIII Symposium, Poznan 15-17 Feb. 1977, Proceedings of Polish Academy of Sciences, 1977 (in Polish).

6. Jankun J. Pazola Z. An Estimation of Wettability and Dissolution Time of Sweetener for Diabetics, Low-calorie Sugar and Some Related Substances. Prace Instytutow i Laboratoriow Badawczych Przemyslu Spozywczego, 1, 1-5, 1977 (in Polish).

7. Jankun J. An Influence of Diameter of Particles of Raw Materials on the Properties of Agglomerated Sugar. Prace Instytutow i Laboratoriow Badawczych Przemyslu Spozywczego, 30, 47-50, 1978 (in Polish).

8. Jankun J. Pazola Z. An Influence of Relative Humidity of Air on Agglomeration of Sugar, Low-calorie Sugar and Sorbitol. Przemysl Spozywczy, 10, 370-372, 1978 (in Polish).

9. Jankun J. Pazola Z. Resistance Measurement of Food Powders as a Method of Estimation its Hygroscopicity and Stability. Ecological Crisis of Environment, Krakow, 26-27 April 1980, Proceedings of Polish Academy of Sciences, 1980.

10. Pazola Z. Einige Probleme der Verpflegung in Verschiedenen Formen von Turismus in VR Polen. Symposium METE, Budapest, 15-19 Sept. 1980, Proceedings of METE.

11. Pazola Z. Jankun J. Characteristische Eigenschaften Pulverartiger Lebensmittel. Symposium METE, Budapest, 15-19 Sept. 1980, Proceedings of METE.

12. Jankun J. Pazola Z. Bistimmung des Klebepunktes von PulverattigenLebensmittel mit Hilfe der Messung Ihre Electrischen Eigenschaften. Kolloquim: Rheologie und Textur von Libensmitteln, Dresden 9-10 Dec. 1981, Proceedings.

13. Jankun J. Pazola Z. Szumala J. A Sticky Point of Food Powders as a Function of Humidity. Committee of Technology and Chemistry of Food, Polish Academy of Sciences, XI Symposium, Szczecin, 11-14 Feb. 1980, Proceedings of Polish Academy of Sciences, 1980 (in Polish).

14. Jankun J. Pazola Z. Wagrowski Z. New Concepts of the Interaction Between a Sphere and a Plane Connected by Bridge of the Fluid. Powder Technology, 28, 107-110, 1981.

15. Pazola Z. Gawecki J. Buchowski M. Korczak J. Jankun J. Grzeskowiak B. Choice of Simple Methods for Quality Control of Frying Fat During Deep Frying of Potato Products. Fette-Seifen-Anstrichmittel, 5, 190-193, 1985 (in German).

16. Karvaly, B., Jankun, J., Trivedi, S., Mallik, B., Kemeny, G. Discrete Charge Carrier Transfer Sites on Proteins? A D.C. Conductivity Study on Ultra-thin Protein Films. Biochemical and Biophysical Research Communication 31; 133(3):1152-1159, 1985.

17. Bombick D. Jankun J. Tullis K. Matsumura F. TCDD (2,3,7,8-tetrachlorodibenzo p-dioxin) Causes Increases in Expression of c-erb-A and Levels of Protein Tyrosine Kinases in Selected Tissues of the Responsive Mouse Strains. Proceedings of National Academy of Science USA, 85, 4128-4132, 1988.

18. Jankun J. Milam DL. Maher VM. McCormick, JJ. Increased Expression of Urokinase Plasminogen Activator is Correlated with Oncogene Induced Transformation of Human Fibroblasts to Malignancy. Fibrinolysis, 3, sup. 1, 25-26, 1989.

19. Jankun J. Matsumura F. Trosko J. Pellicer A. Plasmid-aided Insertion of MMTV LTR and N-ras DNA to NIH 3T3 Cells Makes Them Responsive to 2,3,7,8 TCDD Causing Overexpression of p21ras and Down Regulation of EGF Receptor. Molecular Toxicology, 3, 177-186, 1989.

20. Jankun J. Maher VM. McCormick JJ. Malignant Transformation of Human Fibroblasts by ras Oncogenes and Carcinogens is Correlated with Increased Activity of Receptor Bound Plasminogen Activator. Cancer Research, 51, 1221-1226, 1991.

21. Tullis K. Olsen H. Bombick DW. Matsumura F. Jankun J. TCDD Causes Stimulation of c-ras Expression in the Hepatic Plasma Membranes in vivo and in vitro. J. Biochem Toxicology, 7, 107-116, 1992.

22. Jankun J. Antitumor Activity of the Type-1 Plasminogen Activator Inhibitor and Cytotoxic Conjugate In Vitro. Cancer Research, 52, 5829-5832, 1992.

23. Jankun J. Merrick H. Goldblatt PJ. Expression and Localization of Elements of Plasminogen Activation System in Benign Breast Disease and Breast Cancers. Journal of Cellular Biochemistry, 53, 135-144, 1993.

24. Jankun J. Weigel N. Strobel B. Russell P. Skrzypczak-Jankun E. Selman SH. Plasminogen Activator Inhibitor in Targeted Anticancer Therapy: Treatment of Prostate and Breast Cancers? Proceeding of the XVI International Cancer Congress, 1, 473-478, 1994.

25. Jankun J. Keck RW. Selman SH. Skrzypczak-Jankun E. Swiercz R. Inhibitors of Urokinase Restrict Growth of Prostate Cancer Xenografts in Severe Combined Immunodeficient Mice. Cancer Research, 57, 559-563, 1997.

26. Jankun J. Swiercz R. Selman SH. Skrzypczak-Jankun E. Why Drinking Green Tea Could Prevent Cancer. Nature, 387, 561, 1997.

27. Swiercz R. Wolfe JD. Zaher A. Jankun J. Expression of The Plasminogen Activation System In Kidney Cancer Correlates With its Aggressive Phenotype. Clinical Cancer Research, 4, 869-877,1998.

28. Chau Pham, Jankun J. Skrzypczak-Jankun E. Flowers II RA. Funk MO. Jr. Structural and Thermochemical Characterization of Lipoxygenase Catechol Complexes. Biochemistry, 37:51, 17952-17957, 1998.

29. Jankun J. Skrzypczak-Jankun E. Molecular Basis of Specific Inhibition of Urokinase Plasminogen Activator by Amiloride, Cancer Biochemistry Biophysics, 17; 1-2, 109-123, 1999.

30. Jankun M. Kelly TJ. Zaim A. Young K. Keck RW. Selman SH. Jankun J. Computer Model for Cryosurgery of the Prostate, Computer Aided Surgery, 4: 193-199, 1999.

31. Swiercz R. Skrzypczak-Jankun E. Merrell MM. Selman SH. Jankun J. Angiostatic Activity of Synthetic Inhibitors of Urokinase Type Plasminogen Activator. Oncology Reports, 6: 523-526, 1999.

32. Jankun J. Zaim A. An Image-Guided Robotic System for Photodynamic Therapy of the Prostate,� SPIE Proceeding, 39, 22-29, 1999.

33. Jankun J. Zaim A. Jankun-Kelly M. Keck RW. Selman SH. Computer Model for Photodynamic Therapy of the Prostate. Proceedings of SPIE, 3907: 222-228, 2000.

34. McCabe NP. Angwafo F. III. Zaher A. Selman SH. Kouanche A. and Jankun J. Expression of Soluble Urokinase Plasminogen Activator Receptor May be Related to Outcome in Prostate Cancer Patients, Oncology Reports, 7: 879-882, 2000.

35. Skrzypczak-Jankun E. McCabe PN. Selman SH. and Jankun J. Curcumin Inhibits Lipoxygenase by Binding to its Central Cavity: Theoretical and X-ray Evidence. International Journal of Molecular Medicine, 6: 521-526, 2000.

36. Zaim A. Keck RW. Selman SH. Jankun J. Two-dimensional Ultrasound Image Matching System for Photodynamic Therapy, Proceedings of BIOS-SPIE, 4244: 327-337, 2001.

37. Swiercz R. Keck RW. Skrzypczak-Jankun E. Selman SH. and Jankun, J. Recombinant PAI-1 Inhibits Angiogenesis and Reduces Size of LnCAP Prostate Cancer Xenografts In SCID Mice, Oncology Reports, 8: 463-470, 2001.

38. Jankun J. Skrzypczak-Jankun E. Binding Site of Amiloride to Urokinase Plasminogen Activator Depends on Species, International Journal of Molecular Medicine 8(4): 365-371, 2001.

39. Wojtowicz A. Selman SH. Jankun J. Computer Simulation of Prostate Cryoablation � Fast Approximation of Exact Solution, Computer Aided Surgery, 8:2, 91-97, 2003.

40. Jankun J. Selman SH. Skrzypczak-Jankun E. Control of the Aggressive Capacity of Prostate Cancer by Nutritional Inhibitors of Urokinase and Lipoxygenase, International Journal of Human Genetics, 3(2): 127-134, 2003.

41. Chorostowska-Wynimko J. Swiercz R. Skrzypczak-Jankun E. Wojtowicz A. Selman SH. and Jankun J. Novel Forms of Plasminogen Activator Inhibitor (PAI-1) Created by Cysteine Mutations Extends Half-life; Relevance in Cancer and Angiogenesis, Molecular Cancer Therapeutics, invited paper, 2: 19-28, 2003, (on the cover).

42. Aniola J. Selman SH. Keck RW. Jankun J. Spatial Distribution of Liposome Encapsulated Tin Etiopurpurin Dichloride (SnET2) in the Canine Prostate; Implications for Computer Simulation of Photodynamic Therapy, International Journal of Molecular Medicine 11: 287-291, 2003.

43. Skrzypczak-Jankun E. Zhou K. McCabe NP. Selman SH. Jankun J. Structure of Curcumin in Complex with Lipoxygenase and its Significance in Cancer, International Journal of Molecular Medicine 12:1, 17-25, 2003.

44. Skrzypczak-Jankun E. Zhou K. Jankun J. Inhibition of Lipoxygenase by (-) -Epigallocatechin Gallate: X-Ray Analysis at 2.1� Reveals Degradation of EGCG and Shows Soybean LOX-3 Complex with EGC Instead. Int. J. Mol. Medicine, 12:4, 415-420, 2003.

45. Borbulevych YO. Jankun J. Selman SH. Skrzypczak-Jankun E. Lipoxygenase Interactions with Natural Flavonoid, Quercetin, Reveal a Complex with Protocatechuic Acid in its X-Ray Structure at 2.1 � resolution. Proteins: Structure, Function and Genetics, 54: 13-19, 2004.

46. Lilge L. Pomerleau-Dalcourt N. Douplik A. Selman SH. Keck RW. Szkudlarek M. Pestka M. and Jankun J. Transperineal in vivo Fluence-rate Dosimetry in the Canine Prostate During SnET2-mediated PDT. Phys Med Biol, 49:14, 3209-3225, 2004.

47. Chorostowska-Wynimko J. Swiercz R. Skrzypczak-Jankun E. Selman SH. Jankun J. Plasminogen Activator Inhibitor Type-1 Mutants Regulate Angiogenesis of Human Umbilical and Lung Vascular Endothelial Cells. Oncology Reports, 12:6, 1155-62, 2004.

48. Jankun J. Lilge L. Douplik A. Keck RW. Pestka M. Szkudlarek, M. Stevens PJ. Lee, RJ. Selman SH. Optical Characteristics of the Canine Prostate at 665 nm Sensitized With Tin Etiopurpurin Dichloride: Need for Real-Time Monitoring of Photodynamic Therapy. Journal Urology. 172:2, 739-743, 2004, (on the cover).

49. Chorostowska-Wynimko J. Skrzypczak-Jankun E. Jankun J. Plasminogen Activator Inhibitor Type-1: its Structure, Biological Activity and Role in Tumorigenesis (Review). International Journal of Molecular Medicine, 13:6, 759-756, 2004.

50. Skrzypczak-Jankun E. Borbulevych OY. Jankun J. Soybean Lipoxygenase-3 in Complex with 4-nitrocatechol. Acta Crystallogr D Biol Crystallogr, 60, Pt3, 613-615, 2004.

51. Chorostowska-Wynimko J. Skrzypczak-Jankun E. Jankun J. Plasminogen Activator Inhibitor Type-1 Controls the Process of the in vitro Sprout Formation, J Physiol Pharmacol, 55 Suppl 3, 45-49, 2004.

52. Miocinovic R. McCabe NP. Keck RW. Jankun J. Hampton JA. Selman SH. In vivo and in vitro Effect of Baicalein on Human Prostate Cancer Cells, International Journal of Oncology, 26 (1), 241-246, 2005.

53. E. Skrzypczak-Jankun Borbulevych YO. Melillo A. Keck RW. Soriano-Garcia M. Aniola J. Lilge L. Niedre M. Selman SH. Jankun J. Aspirin Blocks Binding of Photosensitizer SnET2 into Human Serum Albumin; Implications for Photodynamic Therapy. International Journal of Molecular Medicine, 15 (5), 777-783, 2005, (on the cover)

54. Jankun J. Keck RW. Skrzypczak-Jankun E. Lilge L. Selman SH. Diverse Optical Characteristic of the Prostate and Light Delivery System: Implications for Computer Modeling of Prostatic Photodynamic Therapy. British Journal of Urology, 95 (9), 1237-1244, 2005.

55. Zaim A. Jankun J. A Kohonen Clustering Based Approach to Segmentation of Prostate from TRUS Data using Gray-Level Co-occurrence Matrix. Computer Graphics and Imaging, 66-69 2005.

56. Zaim A. Jankun J. An Edge-based Segmentation for Prostate Ultrasound Images Using Phase Symmetry. IEEE International Conference on Signal Analysis and Processing. 1, 297-300, 2006.

57. McCabe NP. Selman SH. Jankun J. Vascular Endothelial Growth Factor Production in Human Prostate Cancer Cells is Stimulated by Overexpression of Platelet 12-Lipoxygenase. The Prostate, 66 (7), 779-787 2006.

58. Jankun J. Specht Z. Szkudlarek M. Greenfield R. Gaikwad B. Trifonov L. Vaugeois J. Aleem AM. Basrur V. Selman SH. Zavodszky IM. Skrzypczak-Jankun E. Plasminogen Activator Inhibitor-1 is Locked in Active Conformation and Polymerizes Upon Binding Ligands Neutralizing its Activity, International Journal of Molecular Medicine, 17 (3), 437-447, 2006, (on the cover).

59. Jankun J. Aleem, AM. Malgorzewicz S. Szkudlarek M. Zavodszky MI Dewitt DL. Feig, M. Selman SH. Skrzypczak-Jankun E. Synthetic Curcuminoids Modulate the Arachidonic Acid Metabolism of Human Platelet 12-Lipoxygenase and Reduce Sprout Formation of Human Endothelial Cells. Molecular Cancer Therapeutics, 5, (5), 1371-1382, 2006, (on the cover).

60. Skrzypczak-Jankun E. Borbulevych YO. Zavodszky, MI. Baranski MR. Padmanabhan K. Petricek V. Jankun, J. Effect of Crystal Freezing and Small-Molecule Binding on Internal Cavity Size in A Large Protein: X-Ray and Docking Studies of Lipoxygenase at Ambient and Low Temperature at 2.0 A Resolution, Acta Crystallogr D Biol Crystallogr, 62, Pt7, 766-775, 2006.

61. Jankun J. Selman SH. Aniola J. Skrzypczak-Jankun E. Nutraceutical Inhibitors of Urokinase: Potential Applications in Prostate Cancer Prevention and Treatment. Oncology Reports, 16, 341-346, 2006.

62. Skrzypczak-Jankun E. Chorostowska-Wynimko J. Selman SH. Jankun J. Lipoxygenases � a Challenging Problem in Enzyme Inhibition and Drug Development. Curr. Enz. Inhib. 3(2), 119-132, 2007, invited paper.

63. Jankun J. Aleem AM. Specht Z. Keck RW. Lysiak-Szydlowska W. Selman SH. Skrzypczak-Jankun E. PAI-1 Induces Cell Detachment, Downregulates Nucleophosmin (B23) and Fortilin (TCTP) in LnCAP Prostate Cancer Cells, Int J Mol Med, 20: 11-20, 2007.

64. Jankun J. Aleem AM. Selman SH. Skrzypczak-Jankun E. Lysiak-Szydlowska W. Fryer H. Greenfield R. VLHL Plasminogen Activator Inhibitor Type One Protects Fibrin Clot from Tissue Plasminogen Activator-induced Fibrinolysis, International Journal of Molecular Medicine, 20(5): 683-687, 2007.

65. Chorostowska-Wynimko J. Kedzior M. Struniawski R. Gruber B. Anuszewska E. Aleem A. Jankun J. The MTT Assay is Not Adequate for the Assessment of Mutated PAI-1 Toxicity Towards Endothelial Cells, Central European Journal of Immunology, 33(4), 2008.

66. Ansari Aleem, Jerzy Jankun, John D. Dignam, Matthias Walther, Hartmut K�hn, Dimitri Svergun, Ewa Skrzypczak-Jankun. Human Platelet 12-Lipoxygenase, New Findings About Its Activity, Membrane Binding and Low Resolution Structure. J. Mol. Biol., 376, 193-209, 2008.

67. Jankun J. Doerks T. Aleem AM. Lysiak-Szydlowska W. Skrzypczak-Jankun E. Do human Lipoxygenases have a PDZ Regulatory Domain? Curr Mol Med. 8, 768-773, 2008.105-107, 2008.

68. Jankun J. Aleem A. Selman SH. Basrur V. Skrzypczak-Jankun, VLHL Plasminogen Activator Inhibitor Spontaneously Reactivates from the Latent to Active Form, International Journal of Molecular Medicine, 23(1), 57-63, 2009, (on the cover).

69. Jankun J. Skrzypczak-Jankun E. Yin and Yang of the Plasminogen Activator Inhibitor. Pol Archives of Internal Medicine, 119(6):410-7, 2009.

70. Jankun J. Aleem AM. Struniawski R. Lysiak-Szydlowska W. Selman SH. Skrzypczak-Jankun E. Accelerated Thrombus Lysis in the Blood of Plasminogen Activator Inhibitor Deficient Mice is Inhibited by PAI-1 with a Very Long Half-life. Pharmacological Reports, 61(4): 673-80, 2009.

71. Aleem AM. Wells L. Jankun J. Walther M. K�hn H. Reinartz J. Skrzypczak-Jankun E. Human Platelet 12-lipoxygenase: Naturally Occurring Q261/R261 Variants and N544L Mutant Show Altered Activity but Unaffected Substrate Binding and Membrane Association Behavior. International Journal of Molecular Medicine, 24(6):759-64, 2009.

72. Jankun J. Selman SH. Keck RW. Lysiak-Szydlowska W. Skrzypczak-Jankun E. Very Long Half-life Plasminogen Activator Inhibitor Type 1 Reduces Bleeding in a Mouse Model. British Journal Urology Int.,105: 1469-1476, 2010.

73. Skrzypczak-Jankun E. Jankun J. Theaflavin digallate inactivates plasminogen activator inhibitor: Could tea help in Alzheimer's disease and obesity? International Journal of Molecular Medicine, 26:1, 45-50, 2010.

74. Jankun J. Keck R. Selman SH. Skrzypczak-Jankun E. Systemic or Topical Application of Plasminogen Activator Inhibitor with Extended Half Life (VLHL PAI-1) Reduces Bleeding Time and Total Blood Loss, International Journal of Molecular Medicine, 26(4):501-504, 2010.

75. Jankun J. Skrzypczak-Jankun E. Bleeding diathesis is associated with A15T heterozygous mutation in exon 2 of plasminogen activator inhibitor type 1 (PAI-1), Experimental and Therapeutic Medicine, 1:4, 575-577, 2010.

76. Jaskiewicz K. Izycka-Swieszewska E. Janiak M. Lysiak-Szydlowska W. Radych K. Reinartz J. Jankun J. Skrzypczak-Jankun E. Platelet 12-lipoxygenase and stem cells in Barrett�s esophagus, Oncology Letters, 1(5), 789-791, 2010.

77. Szefel J. Piotrowska M. Kruszewski WJ. Skrzypczak-Jankun E. Jankun J. Lysiak-Szydlowska W. The Eicosanoids in prevention and management of diseases, Current Molecular Medicine, 11:1, 13-25, 2011.

78. Chorostowska-Wynimko J. Kedzior M. Struniawski R. Jagus P. Skrzypczak-Jankun E. Jankun J. Cell phenotype affects PAI-1 antiproliferative activity � inhibitory effect on the lung cancer but not prostate cancer cells, Pneumonol Alergol Pol, 78:4, 279-83, 2010.

79. Shang W. Svergun DI. Borbulevych OY. Ivanow I. Aleem AM. Jankun J. K�hn H. Skrzypczak-Jankun E. Probing dimerization and structural flexibility of mammalian lipoxygenases by small-angle X-ray scattering, J. Mol. Biol. 409: (4), 654-668, 2011

80. Jankun J. Skotnicka M. Lysiak-Szydlowska W. Al-Senaidy A. Skrzypczak-Jankun E. Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea, International Journal of Molecular Medicine, 27: 525-529, 2011.

81. Jankun J. Skrzypczak-Jankun E. Val17Ile Single Nucleotide Polymorphisms Similarly as Ala15Thr Could be Related to the Lower Secretory Dynamics of PAI-1 Secretion - Theoretical Evidence, Current Molecular Medicine, 11:(6), 512-516, 2011.

82. Jankun J. Protein-based nanotechnology: antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy, International Journal of Oncology, 39: (4), 949-953, 2011.

83. Skotnicka M, Chorostowska-Wynimko J. Jankun J. Skrzypczak-Jankun E. The black tea bioactivity: an overview, Eastern European Journal of Immunology, 36:4, 2011.

84. Jankun J. Yang J. Zheng H. Han F. Al-Senaidy A. Skrzypczak-Jankun E. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure, International Journal of Molecular Medicine, Epub: 29/09/ 2011, 29:1, 61-64, 2012.

85. Jankun J. Al-Senaidy A. Skrzypczak-Jankun E. Can inactivators of plasminogen activator inhibitor alleviate burden of obesity and diabetes? (Review), Epub: 10/14/2011, 27:4, 525-529, 2012, on the cover.

86. Szefel J Kruszewski WJ. Ciesielski M. Szajewski M. Kawecki K. Jankun J. Lysiak-Szydlowska W. L-Carnitine and cancer cachexia. Part I: L-Carnitine distribution and metabolic disorders in cancer cachexia. Epub: May 4, 2012 Doi: 10.3892/or.2012.1804, 28: 324-329, 2012.

87. Szefel J Kruszewski WJ. Ciesielski M. Szajewski M. Kawecki K. Ewa Aleksandrowicz-Wrona Jankun J. Lysiak-Szydlowska W. L-Carnitine and cancer cachexia. Part II Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes. Epub: May 4, 2012, Doi: 10.3892/or.2012.1805, 28: 319-323, 2012.

88. Jankun J. Al-Senaidy A. Skrzypczak-Jankun E. Could Drinking Black Tea Fight Diabetes; Literature Review and Theoretical Indication. Eastern European Journal of Immunology, 37:2, 2012.

89. Skrzypczak-Jankun E. Jankun J. Al-Senaidy A. Human Lipoxygenase: Recent Developments in its Structure, Function, Relevance to Diseases and Challenges in Drug Development. Current Medicinal Chemistry, 2012, 19.

90. Gohara A, Eltaki N. Sabry D. Murtagh D. Khuder S, Jankun J. Selman SH. Skrzypczak-Jankun E. Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer. Oncology Reports, Epub: July 20, 2012, Doi: 10.3892/or.2012.1924

91. Malik AM. Al-Senaidy A. Skrzypczak-Jankun E. Jankun J. What is the anti-diabetic agent of camel milk? International Journal of Molecular Medicine, Epub: Friday, June 29, 2012 Doi: 10.3892/ijmm.2012.105, 30:3, 585-592, 2012.

92. Jankun J. Challenging delivery of VLHL NS PAI-1 by osmotic pumps in diabetic mouse; Case report. Experimental and Therapeutic Medicine, Epub: July 17, 2012, Doi: 10.3892/etm.2012.63.

93. Jankun J. Skrzypczak-Jankun E. Plasminogen Activator Inhibitor with very long half-life (VLHL PAI-1) could reduce bleeding in PAI-1 deficient patients. Cardiovascular & Hematological Disorders - Drug Targets, 13, 2, 144-150, 2013.

94. Malgorzewicz S. Skrzypczak-Jankun E. Jankun J. Plasminogen Activator Inhibitor (PAI-1) in kidney pathology, Published online on: Thursday, January 10, 2013, Doi: 10.3892/ijmm.2013.12342013.1234, 31: 503-510, 2013.

95. Malik A. Al-Senaidy A. Skrzypczak-Jankun E. Jankun J. Isolation and characterization of serum albumin from Camelus dromaderies, Published online on: Thursday, June 6, 2013, Doi: 10.3892/etm.2013.1145.

96. Jankun J. Prosperity Over the World: From Pies and Fries to PAI. Accepted.

97. Jankun J. Kondray V. Skrzypczak-Jankun E. Analysis of Inhibition of PAI-1 by Theaflavins Metal Complexes and their Degradation Products, Published online on: Tuesday, March 19, 2013, Doi:10.3892/ijmm.2013.1308, International Journal of Molecular Medicine, 31:5, 1153-1158, 2013, on the cover.

98. Piotrowska M. Skrzypczak-Jankun E. Szefel J. Lysiak-Szydlowska W. Szajewski M. Aleksandrowicz-Wrona E. Jankun J. The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate, accepted.

99. Jankun J. Skrzypczak-Jankun E. Lipinski B. Complex function of magnesium in blood clot formation and lysis, accepted.

100. Parsai S. Keck R. Skrzypczak-Jankun E. Jankun J. Analysis of Anticancer Activity of Curcuminoids, Thiotryptophan and 4-Phenoxyphenol Derivatives, accepted Oncology Letters.

101. Jankun J. Landeta P. Pretorius E. Skrzypczak-Jankun E. Lipinski B. Unusual Clotting Dynamics of Plasma Supplemented with Iron(III), Submitted.

102. Jankun J. If Nature failed creating the perfect prostate could inhibitors of proteolysis help? Submitted.

103. Szajewski M. Kruszewski W.J. Lakomy J. Ciesielski M. Kawecki K. Jankun J. Buczek T. Szefel J. VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma. Submitted.

104. Jankun J. Keck RW Selman SH. Epigallocatechin-3-Gallate Prevents Tumor Cell Implantation/Growth in an Experimental Rat Bladder Tumor Model. Submitted.

105. Malgorzewicz S. Dardzinska JA. Gnacinska M., Jankun J, Bryl B. Sworczak K. Complex interaction between the immune system and adipose tissue. Submitted.

PROTEIN STRUCTURE ENTRIES IN PROTEIN DATA BANK:

1. 1BYT, Skrzypczak-Jankun E. Jankun J. Pham VCh. Flowers RH. Funk MO. Lipoxygenase-3 (Soybean) in Complex with 4-nitrocatechol (2.6 �), 1998, replaced by 1NO3.

2. 1HU9, Zhou K. Skrzypczak-Jankun E. McCabe NP. Selman SH. Jankun J. Lipoxygenase-3 (Soybean) Complex with 4-hydroperoxy-2-methoxy-phenol. Deposition date: 04-Jan-2001, Release Date: 03-Jun-2003

 

3. 1JNQ, Zhou K. Skrzypczak-Jankun E. McCabe NP. Funk MO. Selman SH. Jankun J. Lipoxygenase-3 (Soybean) Complex with EGC. Deposition date: 24-Jul-2001, Release Date: 03-Jun-2003.

4. 1N8Q, Borbulevych OY. Jankun J. Selman SH. Skrzypczak-Jankun E. Lipoxygenase-3 (Soybean) in Complex with Protocatechuic Acid. Deposition date: 21-Nov-2002, release date: 03-Jun-2003.

5. 1NO3, Borbulevych OY. Jankun J. Skrzypczak-Jankun E. Lipoxygenase-3 (Soybean) in Complex with 4-nitrocatechol, Deposition date: 15-Jan-2003, Release date: 03-Jun-2003.

6. 1RRH, Borbulevych OY. Jankun J. Skrzypczak-Jankun, E. Soybean Lipoxygenase (LOX-3) at Ambient Temperatures at 2.0 � Resolution, Deposition date: 08-Dec-2003, Release date: 21-Dec-2004.

7. 1RRL, Borbulevych OY. Jankun J. Skrzypczak-Jankun E. Soybean Lipoxygenase (LOX-3) at 93K at 2.0 � Resolution, Deposition date: 08-Dec-2003, Release date: 21-Dec-2004.

8. 3R4L, Yang J. Zheng H. Han Q. Skrzypczak-Jankun E. Jankun J. Human Very Long Half Life Plasminogen Activator Inhibitor Type-1. Deposition date: 17-March-2011.

PATENTS:

1. Jankun J. Method of Measuring Concentration of Ions and Method of Regeneration of Water Purifying Column, Polish Patent, P-78904, May, 5, 1976.

2. Jankun J. Jaskula W. Cieslak J. Kwiatkowski F. Przymuszala W. Method of Measuring Solubility of Powders. Polish Patent W-29391, November 21, 1978.

3. Pazola Z. Cieslak J. Jankun J. Skorupska I. Manner of production of sweetener for diabetics and concentrated drinks based on it. Polish Patent P. 190364 October 06, 1976.

4. Jankun J. Hart R. Method of Delivery of a Cytotoxic Compound to a Cancer Cells Using a Pathway of Biologically Active Material. U. S. Patent 5,679,350, October 21, 1997. International application: WO/1993/024141; Designated States: AU, BR, CA, JP, NO; European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

5. Jankun J. Swiercz R. Skrzypczak-Jankun E. Chorostowska-Wynimko J. Selman SH. Modified Plasminogen Activator Inhibitor Type-1 and Methods Bases Thereon. USPTO Application #: 20050158295, International application: WO/2003/080646.

USA patent has been issued: United States Patent 7,592,422

European patent has been issued: 1,487,867

Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

African Regional Intellectual Property Org. (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)

Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)

European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)

African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

6. Jankun J. Skrzypczak-Jankun, E., Selman, S.H. Mutated Plasminogen Activator Inhibitor Type One, filed as the provisional patent at April 28, 2007, U.S.

Provisional Application No. 60/926,797, in 2008 as a regular patent in USA and WTO.

Intended for:

Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

African Regional Intellectual Property Org. (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)

Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)

European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)

7. Jankun J. Skrzypczak-Jankun E. Selman SH. Greenfield R. Methods of Treatment Using Modified PAI-1 Molecules, filed as the provisional patent at October 1, 2007, U.S. Provisional Application No. 60/976,651, in 2008 as a regular patent in USA and WTO. US. Patent: 8,211,858.

Intended for:

Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

African Regional Intellectual Property Org. (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)

Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)

European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)

8. Jankun J. Skrzypczak-Jankun E, Theaflavin Digallate as Inactivator of Plasminogen Activator Inhibitor (PAI-1) and Methods and Materials for the Treatment of Alzheimer�s Disease and Obesity, filed as the provisional patent at March 2, 2010, Ser. No. 61/308,754, MST File No.: 1-51691 Inventors.

Intended for:

Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

African Regional Intellectual Property Org. (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)

Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)

European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)

LICENSED TECHNOLOGY:

1. Method of Crystallization of Vanillin.

2. Method of Delivery of a Cytotoxic Compound to a Cancer Cells Using a Pathway of Biologically Active Material.

3. Modified Plasminogen Activator Inhibitor Type-1 and Methods Bases Thereon.

4. Human P-12-lipoxygenase and Antibody.

BOOKS:

1. Jankun J. Pazola, Z., Olejnik. D., Food and Nourishment, AWF, Poznan, 1981.

2. Jankun J. Targeting of Drugs to Tumors: The Use of Plasminogen Activator Inhibitor as a Ligand. Edited by G. Gregoriadis, chapter in: Targeting of Drugs: Advances in System Constructs. NATO ASI Series, 1993.

3. Jankun J. VLHL PAI-1 as Anticancer Agent, doctor of science thesis, (printed as book in Polish), Medical University Gdansk, Gdansk, Toledo, 2007.

PRESENTATIONS:

1. Jankun J. Plasminogen Activation and Cancer. University of Michigan, Department of Dermatology, February 1990.

2. Jankun J. Proteolysis and Cancer. Illinois Research Institute of Technology, Chicago, April 1990.

3. Jankun J. Fibrinolysis and Cancer. Invited conference panelist. Sponsored by American Diagnostica Inc., La Guardia, January 31, 1992.

4. Jankun J. Histopathological Localization of Elements of Plasminogen Activation System in Breast and Prostate Cancers. Medical School at Gdansk, Gdansk, Poland, July 6, 1992.

5. Jankun J. PAI-1 as a Localizing and Internalizing Element of Tumor Targeting by PAI-1 Cytotoxic Conjugate. Invited conference lecturer. NATO Advanced Studies Institute, Cape Sounion Beach, Greece, June 24 - July 5, 1993.

6. Jankun J. Plasminogen Activator Inhibitor in Targeted Anticancer Therapy: Treatment of Prostate and Breast Cancers? Invited congress lecturer. XVI International Cancer Congress, New Delhi, India, October/November 1994.

7. Jankun J. Proteolysis and Cancer, Cost or Great Hope. The University of Toledo, Toledo, Center for Bioengineering, February 9, 1996.

8. Jankun J. Inhibitors of Urokinase as Anticancer Drugs - Green Tea Connections. The University of Toledo, Department of Chemistry, Toledo, June 7, 1997.

9. Jankun J. Proteolysis in Cancer and Treatment, Medical College of Ohio, Toledo, March 5, 1998.

10. Jankun J. Jankun, M., TJ Kelly, Selman S. H. Simulation of Prostate Cryoablation, Computer Assisted Minimally Invasive Symposium, Cleveland, April 5-6, 1998.

11. Jankun J. Jankun M. Kelly TJ. Selman SH. Simulation of Prostate Cryoablation, X Congress of Cryosurgery, Orlando, October 29 � November 1, 1998.

12. Jankun J. Swiercz R. Selman SH. Skrzypczak-Jankun E. Practical Applications of Bioinformatics: Why Drinking Green Tea May Prevent Cancer? Workshop, Bioinformatics; from Data to Knowledge, Committee for Biochemistry and Biophysics of the Royal Netherlands Academy of Arts and Sciences, Purmerend, The Netherlands, April 8-9, 1999, Invited lecturer.

13. Jankun J. Angiostatic Activity of Urokinase Inhibitors, Wright State University, Department of Biochemistry and Molecular Biology, April 29, 1999.

14. Jankun J. Urokinase Inhibitors from Protein Target to Anti-cancer Drug. Bowling Green State University, June 4, 1999.

15. Jankun J. Swiercz R. Skrzypczak-Jankun E. Merrell M. M. Selman HS. Inhibitors of Urokinase as an Anti-cancer and Angiogenic Agents. 2nd International Symposium on Molecular Medicine, October 7-9, 1999, Vouligameni, Athens, Greece, invited speaker.

16. Jankun M. Kelly TJ. Zaim A. Young K. Keck, RW. Selman SH. and Jankun J. Computer Simulation of Cryoablation of Prostate Cancer, 4th World Congress on Advances in Oncology, October, 7-9, 1999, Vouligameni, Athens, Greece, invited speaker.

17. Jankun J. Zaim A. Jankun-Kelly M. Keck RW. Selman SH. Computer Model for Photodynamic Therapy of the Prostate. BIOS-SPIE, January 21-26, 2000, San Jose.

18. Jankun J. Zaim A. Jankun-Kelly M. Keck RW. Selman SH. Computer Simulation of Photodynamic Therapy of the Prostate. Twentieth Annual Meeting, April 7-9, 2000, Reno, Nevada.

19. Skrzypczak-Jankun E. Brault PA. Bross R. Funk MO, McCabe NP, Jankun J. �Purple� Lipoxygenase � X-ray Analysis with Three Different Peroxides. American Crystallographic Association Annual Meeting, July 22-27, 2000, St. Paul, Minnesota.

20. Jankun J. McCabe NP. Selman SH. Soluble Urokinase Plasminogen Activator Receptor as Potential Biomarker of Prostate Cancer Progression. 5th World Congress on Advances in Oncology, October 19-21, 2000, Hersonissos, Crete, Greece, invited speaker.

21. Skrzypczak-Jankun E. McCabe NP. Selman SH. Jankun J. Lipoxygenase Inhibitors � Potential Anti-Cancer Agents.5th World Congress on Advances in Oncology, October 19-21, 2000, Hersonissos, Crete, Greece.

22. Zaim A. Keck RW. Selman SH. Jankun J. Two-dimensional Ultrasound Image Matching System for Photodynamic Therapy, BIOS-SPIE, January 21-26, 2001, San Jose.

23. Jankun J, Swiercz R. McCabe NP. Selman SH. Skrzypczak-Jankun E. Curcumin and Green Tea Could Prevent Cancer Formation, the Biochemical and X-Ray Evidence. Nourishment in Successful Aging. May 18, 2001, Gdansk, Poland.

24. Jankun J. Swiercz R. McCabe NP. Selman SH. Skrzypczak-Jankun E. Anticancer Agents in Food and Mechanism of Action. Cieszkowski University, Food Technology Department, May 23, 2001, Poznan, Poland.

25. Jankun J. Swiercz R. Selman SH. Skrzypczak-Jankun E. Engineered Urokinase Plasminogen Activator Inhibitor Prevents Angiogenesis. 6th World Congress on Advances in Oncology, October 18-20, 2001, Hersonissos, Crete, Greece invited speaker.

26. Skrzypczak-Jankun E. Selman SH. Jankun J. Diverse Binding of Urokinase Inhibitors Depends on Species; Does Animal Model Provides Conclusive Evidence? 6th World Congress on Advances in Oncology, October 18-20, 2001, Hersonissos, Crete, Greece.

27. Jankun J. Green Tea and its Effects on Cancer. American Chemical Society, February 20, 2002, Toledo, invited speaker.

28. Chorostowska-Wynimko J. Swiercz R. Skrzypczak-Jankun E. Aniola J. Selman SH. McCabe NP, Jankun J. Cysteine Mutations of Plasminogen Activator Inhibitor Type 1 Extend its Half-life � Implication for Inhibition of Cancer Angiogenesis. Annual Meeting of American Association for Cancer Research, April 6-11, 2002, San Francisco.

29. Jankun J. Suppression of Angiogenesis and Tumor Growth by Urokinase Plasminogen activator inhibitors. Annual Meeting of Society for Basic Urologic Research, May 25, 2002, Orlando, invited speaker.

30. Jankun J. Selman SH. Chorostowska-Wynimko J. Skrzypczak-Jankun E. Regulation of Angiogenesis by Urokinase Plasminogen Activator System. 7th World Congress on Advances in Oncology, October 10-12, 2002, Hersonissos, Crete, Greece invited speaker.

31. Jankun J. Urokinase Angiogenesis and Cancer, 2003 MCO Molecular Pathogenesis of Cancer Training Program Retreat. Maumee Bay January 23-24, 2003.

32. Jankun J. Ultrasound Enhancing Agents for Prostate Cancer Detection. Pharmacy Department, The University of Toledo, Toledo, October 15, 2004.

33. Jankun J. Photodynamic Therapy of Prostate Cancer. University of Tennessee, School of Veterinary Medicine, Knoxville, October 19, 2004.

34. Jankun J. PAI-1 and Cancer. Biochemistry Department, Michigan State University, East Lansing, December 2, 2004.

35. Jankun J. Photodynamic Therapy of Prostate Cancer. Highland University at New Mexico, Las Vegas, February 10, 2005.

36. Jankun J. About �Chanelli� NOL and Healthy Food. Cieszkowski University, Food Technology Department, May 13, 2005, Poznan, Poland.

37. Jankun J. Aleem A. Specht Z. Selman SH. Skrzypczak-Jankun E. Rational Design of Cysteine mutants of PAI-1 with Very Long Half-lives, 18th International Congress on Fibrinolysis and Proteolysis, August 27-31, 2006 - San Diego, CA, USA.

38. Jankun J. Plasminogen Activator Inhibitor Type-1 in Anticancer Therapy, Washington State University, Department of Pharmaceutical Sciences, Pullman, March, 8, 2007.

39. Jankun J. Polyphenols and their Potential Health Benefits, Medical University of Gdansk, Gdansk, Poland, April, 13, 2007.

40. Jankun J. About �Chanelli� and Healthy Food, Medical University of Gdansk, Gdansk, Poland, October 13, 2007.

41. Jankun J. Therapeutic Applications of Plasminogen Activator Inhibitor with Very Long Half Life. Medical University of Gdansk, Gdansk, Poland, December 8, 2008.

42. Jankun J. Can Light be Therapeutic? Medical University of Gdansk, Gdansk, Poland, December 11, 2008.

43. Jankun J. Nutraceutical Inhibitors of Urokinase and Lipoxygense. Medical University of Gdansk, Gdansk, Poland, December 13, 2008.

44. Jankun J. Selman SH. Aleem AM. Keck R. Skrzypczak-Jankun E. PAI-1 with Very Long Half-life Controls Bleeding. Molecular & Cellular Biology of Plasminogen Activation, March 31- April 4, 2009, Cold Spring Laboratory.

45. Jankun J. Skrzypczak-Jankun E. Lipoxygenase and Urokinase in diseases. Medical University of Gdansk, Gdansk, Poland, October 5, 2009.

46. Skrzypczak-Jankun E Eltaki N. Gohara A. Jankun J. Lysiak-Szydlowska W. Piotrowska M. Lipoxygenase � a challenging target in human diseases, Zing Conference, Medicinal Chemistry Conference, Sharm el Sheikh, Egypt, February 22-25, 2011.

47. Jankun J. and Skrzypczak-Jankun E. Recombinant Plasminogen Activator Inhibitor with Extended Half-life in Therapy, Zing Conference, Medicinal Chemistry Conference, Sharm el Sheikh, Egypt, February 22-25, 2011.

48. Jankun J. Plasminogen activation system in physiology and pathology, King Saud University, Riyadh, Saudi Arabia, distinguish scientist program, Protein Research Chair, January 5, 2011.

49. Jankun J. Antioxidants of green and black tea, King Saud University, Riyadh, Saudi Arabia, distinguish scientist program, Protein Research Chair, January 8, 2011.

50. Jankun J. Modern methods of protein purification, Riyadh, Saudi Arabia, distinguish scientist program, King Saud University, Protein Research Chair, January 11, 2011.

51. Jankun J. Skrzypczak-Jankun E. Nutraceuticals In prostate cancer. XIII Zjazd PTZPiD, Jachranka, Polska, June, 15 -19, 2011, invited speaker.

52. Jankun J. Plasminogen Activation Inhibitor in Diabetes, Riyadh, Saudi Arabia, distinguish scientist program, King Saud University, Protein Research Chair, October, 2011.

53. Jankun J. Plasminogen Activation Inhibitor as a Nanodevice; Can engineered protein cure diseases?, Riyadh, Saudi Arabia, distinguish scientist program, King Saud University, Protein Research Chair, October, 2011.

54. Jankun J. Selman SH. Al-Senaidy A. Skrzypczak-Jankun E. Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) in cancer, PAI-1 deficiency and diabetes therapy. Track: Protein and Peptide Sciences (SL), 4th International Conference on Drug Discovery and Therapy. Dubai, United Arab Emirates, February 12-15, 2012.

55. Jankun J. Al-Senaidy A. and Skrzypczak-Jankun E. Recombinant Plasminogen Activator Inhibitor with Extended Half-life in Cancer and Bleeding Therapy, Zing Conference, Medicinal Chemistry Conference, Lanzarote, Spain, March 2-5, 2012.

56. Jankun J. Biochemical evidence of holistic approaches to disease treatment. Riyadh, Saudi Arabia, distinguish scientist program, King Saud University, Protein Research Chair, 15 April, 2012.

57. Jankun J. Camel milk and diabetes - what is the active agent? Riyadh, Saudi Arabia, distinguish scientist program, King Saud University, Protein Research Chair, 17 April, 2012.

58. Jankun J. New insides to protein structure modeling. Riyadh, Saudi Arabia, distinguish scientist program, King Saud University, Protein Research Chair, 19 April, 2012.

59. Jankun J. Skrzypczak-Jankun E. Nutraceuticals inhibit PAI-1 and alleviate symptoms of diabetes. XIV Zjazd PTZPiD, Jachranka, Poland, June, 18-20, 2012, invited speaker.

60. Jankun J. 9th Annual Integrative Medicine Conference, Wellness Across the Age Spectrum, Natural inhibitors of PAI-1 in diabetes. Toledo, September 21, 2012, invited speaker.

61. Jankun J, From pie to PAI-1, Wellness Across the World, Third International Conference, Kwidzyn, Poland, October 27, 2012, invited speaker.

SYMPOSIA:

1. 4th World Congress on Advances in Oncology, October 7-9, 1999, Vouligameni, Athens, Greece. Co-chairman, session on endocrinology and molecular biology of cancer.

2. 5th World Congress on Advances in Oncology, October 19-21, 2000.Hersonissos, Crete, Greece. Chairman, session on prostate cancer.

3. 6th World Congress on Advances in Oncology, October 18-20, 2001, Hersonissos, Crete, Greece. Chairman of session on angiogenesis/metastasis.

4. 7th World Congress on Advances in Oncology, October 10-12, 2002, Hersonissos, Crete, Greece. Chairman of session on angiogenesis.

5. MCO Molecular Pathogenesis of Cancer Training Program Retreat. Maumee Bay, January 23, 2003, moderator.

6. 8th World Congress on Advances in Oncology, October 12-14, 2002, Hersonissos, Crete, Greece. Invited Chairman.

ABSTRACTS:

1. Jankun J. Maher VM. McCormick JJ. Urokinase Receptors on Human Fibroblasts: Correlation Between Increase in Receptor Numbers and Malignant Phenotype. Tenth International Congress on Fibrinolysis, Indianapolis, August 4 - 8, 1990.

2. Jankun J. Maher VM. McCormick JJ. Quantification of the Urokinase and Tissue Plasminogen Activators Activity of the Malignantly Transformed Human Fibroblasts. Keystone Symposia on Molecular and Cellular Biology � Proteolysis in Regulation and Disease, Keystone, April 7 - 14, 1991.

3. Jankun J. Maher VM. McCormick JJ. Increase in the Receptor-bound Urokinase Plasminogen Activator Activity is a Marker for Malignant Transformation of Human Fibroblasts. Third International Workshop on the Molecular and Cellular Biology of Plasminogen Activation, Elsinore, Denmark, May 8 - 13, 1991.

4. Garbo G. Mastroiani M. Jankun J. Keck RW. Selman SH. Morgan AR. Tinetiopurpurin Pharmacokinetics Studies in Rodents. Nineteenth Annual Meeting of American Society for Photobiology, San Diego, August 24 - 26, 1991.

5. Jankun J. Tumor Associated Proteolysis; Anti Urokinase Monoclonal Antibody Conjugates in Therapy of Cancer. Keystone Symposia on Molecular and Cellular Biology - Breast and Prostate Cancer, Lake Tahoe, March 7 - 13, 1992.

6. Jankun J. Hart R. Study of the Tumor Targeting by the Type-1 Plasminogen Activator Inhibitor and Cytotoxic Conjugates. Eleventh International Congress on Fibrinolysis, Copenhagen-Denmark, June 29 - July 3, 1992.

7. Jankun J. The Urokinase Plasminogen Activator Pathway as a Novel Mechanism of Tumor Targeting and Cell Membrane Traversal. Keystone Symposia on Molecular and Cellular Biology - Cell Compartmentalization, Taos, February 8 - 14, 1993.

8. Jankun J. Expression and Localization of Elements of Plasminogen Activation System in Breast Tumors. Fourth International Workshop on Molecular and Cellular Biology of Plasminogen Activation. Cold Spring Harbor, September 28 -October 3, 1993.

9. Jankun J. Antitumor Activity of Plasminogen Activator Inhibitor Type 1 � Saporin Cytotoxin In Vitro. Fourth International Workshop on Molecular and Cellular Biology of Plasminogen Activation. Cold Spring Harbor, September 28 � October 3, 1993.

10. Jankun J. PAI-1 in Anticancer Targeted Therapy, CHI Conference on New Cancer Strategies, Philadelphia, October 18-19,1993.

11. Jankun J. Merrick H., Demonstration of Plasminogen Activation System in Malignant and Benign Breast Disease by Immunohistological Staining, 48th Annual Cancer Symposium of Society of the Surgical Oncology, Boston, March 23-26, 1995.

12. Jankun J. Skrzypczak-Jankun E. Molecular Modeling of Urokinase Inhibition by Carbenicillin and Ampicillin, XIIth International Congress on Fibrinolysis and Thrombolysis, Barcelona, Spain, June 24-28, 1996.

13. Skrzypczak-Jankun E. Chau M. Phuam V. Flowers RM. Jankun J. Funk MO. Soybean Lipoxygenase-3, Complexes with Small Molecules. American Crystallographic Association, Arlington, June 19-25, 1998.

14. Merrell MM. Swiercz R. Skrzypczak-Jankun E. Selman HS. and Jankun J. Angiostatic Activity of Synthetic Inhibitors of Urokinase Type Plasminogen Activator. Annual Meeting of Ohio Urological Society, 1st Place in Resident Essay Contest (MMM) March 20, 1999, Columbus; also Annual Meeting of Toledo Surgical Society, 1st Place in Resident Research Contest, (MMM), March 25, 1999, Toledo.

15. Jankun J. McCabe NP. Angwafo FF. III, Selman SH. High Expression of Soluble Urokinase-Type Plasminogen Activator Correlates with High Risk in Prostate Cancer Patients. 35th ASCO Annual Meeting, Atlanta, 15-18, May 1999.

16. Zaim A, Selman SH, Keck R, Jankun J. Three-dimensional Visualization and Simulation for Photodynamic Therapy of the Prostate. 1st Annual Photochemical Science Day, March 22, 2000, Bowling Green.

17. Zaim A, Keck R, Selman SH, Jankun J. An Image-guided Robotic System for Photodynamic Therapy, Paper TH-CXH-19. World Congress on Medical Physics and Biomedical Engineering, Chicago, July 23-28, 2000.

18. Jankun J. Swiercz R. Selman SH. Skrzypczak-Jankun E. Inhibitors of Urokinase Plasminogen Activator Prevent Angiogenesis. XVth International Congress on Fibrinolysis and Proteolysis, Hamamatsu, Japan, June 25-29, 2000.

19. Skrzypczak-Jankun E. Zhou K. McCabe NP. Kernstock R. Selman SH, Funk, MO. Jankun J. Natural Polyphenols in Complexes with Lipoxygenase � Structural Studies and their Relevance to Cancer. Annual Meeting of American Association for Cancer Research, April 6-11, 2002, San Francisco.

20. Jankun J. Chorostowska-Wynimko J. Selman SH. Skrzypczak-Jankun E. Recombinant Plasminogen Activator Inhibitor in Anti-cancer Therapy. Department of Defense Breast Cancer Research Program Meeting, Orlando, Florida, September 25-28, 2002.

21. Skrzypczak-Jankun E. Kernstock R. Funk MO. Borbulevych YO. Jankun J. Regulating Fatty Acid Metabolism Helps to Fight Cancer: Structural Studies of Lipoxygenase Inhibited with Quercetin and other Dietary Isoflavones, 7th World Congress on Advances in Oncology, October 10-12, 2002, Hersonissos, Crete, Greece.

22. Skrzypczak-Jankun E. Borbulevych OY. Selman SH, Jankun J. Blocking Fatty Acid Metabolism as Means to Target Cancer: X-ray Studies of Lipoxygenase Inhibition by Quercetin. American Association for Cancer Research 2003 Annual Meeting, Toronto, April 2003.

23. Jankun J. Selman SH. Lilge L. Keck R. Aniola J. Significance of Spatial Distribution of Tin Etiopurpurin Dichloride (SnET2) in the Prostate for Computer Simulation of Photodynamic Therapy. American Association for Cancer Research 2003 Annual Meeting, Toronto, April 2003.

24. Chorostowska-Wynimko J. Skrzypczak-Jankun E. Jankun J. Function of PAI-1 in Lung Cancer (in Polish). IGiChP OT Rabka-Zdr�j, Acta Pneumonologica et Alergologica Pediatrica, supplement 1, vol.6, 2003.

25. Skrzypczak-Jankun E. Zhou K. Borbulevych OY. Jankun J. Lipoxygenase Complexes with Natural Flavonoids � Biotransformation or an Artifact of X-ray Analysis? American Crystallographic Association, Annual Meeting, Cincinnati, OH, July 26-31, 2003.

26. Borbulevych OY. Jankun J. Skrzypczak-Jankun E. X-Ray Structural Studies of Soybean Lipoxygenase-3 (LOX-3) at Ambient and 93K Temperatures at 2� Resolution. American Crystallographic Association, Annual Meeting, Cincinnati, OH, July 26-31, 2003. Honorable mention of poster in the Oxford Cryosystem Low Temperature, Prize for OYB.

27. Chorostowska-Wynimko J. Swiercz R. Skrzypczak-Jankun E. Selman S. Jankun J. Human Lung Microvascular Endothelial Cells (HMVEC-L) Angiogenic Activity is Inhibited by Stable Plasminogen Activator Inhibitor-1 (PAI-1) Mutants via Urokinase-dependent Pathway. European Respiratory Journal 2004, 24, suppl.48, P160. 14th Annual Congress of the European Respiratory Society, September, 4-8, 2004, Glasgow, Scotland.

28. Chorostowska-Wynimko J. Swiercz R. Skrzypczak-Jankun E. Selman SH. Jankun J. Human Lung Microvascular Endothelial Cells (HMVEC-L) Angiogenic Activity is Inhibited by Stable Plasminogen Activator Inhibitor-1 (PAI-1) Mutants via Urokinase-dependent Pathway, Symposium: Pharmacoepidemiology of obstructive lung disease: beyond clinical trial, October 15 � 17, 2004, Lausanne, Switzerland

29. Chorostowska-Wynimko J. Skrzypczak-Jankun E. Selman SH. Jankun J. The Mechanism of Plasminogen Activator Inhibitor Type-1 (PAI-1) Cys Mutants Inhibitory Activity Towards Lung Capillaries Endothelial Cells (HMVEC-L), European Respiratory Society Annual Meeting, Copenhagen, September 17-21, 2005.

30. Chorostowska-Wynimko J. Skrzypczak-Jankun E. Selman SH. Jankun J. Plasminogen Activator Inhibitor Type 1 (PAI-1) Mutants of Extended Half-life Time Inhibit Angiogenic Activity of Human Lung Microvascular Endothelial Cells - Mechanism of Action (in Polish). Adv. Clin. Exp. Med. 2005: 14 (2B) s.91-95, January, 13-16. 2005, Szklarska Poreba, Poland.

31. Chorostowska-Wynimko J. Swiercz R. Skrzypczak-Jankun E. Selman S. Jankun J. The Mechanism of Plasminogen Activator Inhibitor Type-1 Cys Mutants Inhibitory Activity Towards Lung Capillaries Endothelial Cells (HMVECL). International Journal of Molecular Medicine 2005,16, supp1,36, 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine and Cancer Chemoprevention Symposium, October 11-13, 2005, Hersonissos, Crete, Greece.

32. Aleem AM. Specht, Z. Selman SH. Skrzypczak-Jankun E. Jankun J. Expression and Purification of Cysteine Mutants of PAI-1 with Very Long Half-lives. 18th International Congress on Fibrinolysis and Proteolysis, August 27-31, 2006 � San Diego, CA, USA.

33. Skrzypczak-Jankun E. Jankun J. Toward Understanding of Human Lipoxygenases, Structural Methods in Chemistry, Biology and Medicine, Workshop in memory of Prof. Yu.T.Struchkov, Chicago, August 10-13, 2007.

34. Aleem AM. Jankun J. Svergun D. Guo L. Walther M. K�hn H. Skrzypczak- Jankun E. Low Resolution Structure and Functional Properties of Recombinant Human Platelet 12-lipoxygenase. X International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, Montreal 16-19 September 2007.

35. Chorostowska-Wynimko J. Kedzior M. Szpechcinski, A. Gruber B. Januszewska A. Aleem, A. Skrzypczak-Jankun E. Jankun J. Immunomodulatory Effect of PAI-1 on the Lung Cancer Cells. Central European Journal of Immunology 2008, Vol.33 (Suppl.I):120.XIII, Congress of Polish Society of Experimental and Clinical Immunology, Krakow, 14-17, May, 2008.

36. Chorostowska-Wynimko J. Kedzior M. Szpechcinski A. Gruber B. Anuszewska A. Aleem A. Skrzypczak-Jankun E. Jankun J. PAI-1 Negatively Controls the Lung Cancer Cells Proliferation. Endoscopic Review 2008, Vol. 13 (29):69, 11th Central European Lung Cancer Conference, 12-14, June, 2008, Ljubljana, Slovenia.

37. Jankun J. Aleem A. Struniawski R. Lysiak-Szydlowska W. Selman SH. Skrzypczak-Jankun. Accelerated Thrombus Lysis in Blood of Plasminogen Activator Inhibitor Deficient Mice is Inhibited by Very Long Half-Life PAI-1. Molecular & Cellular Biology of Plasminogen Activation, March 31- April 4, 2008, Cold Spring Laboratory.

38. Jankun J. Skrzypczak-Jankun. Theaflavin Digallate Inactivates Plasminogen Activator Inhibitor (PAI-1). Congress of International Society of Fibrinolysis and Proteolysis (ISFP) 2010, Amsterdam, The Netherlands, August 23-25, 2010.

39. Jankun J. Al-Senaidy A. Skrzypczak-Jankun E. Nutraceutical inhibitors of plasminogen activator inhibitor (PAI-1) in diabetes therapy.4th International Conference on Drug Discovery and Therapy. Dubai, United Arab Emirates, February 12-15, 2012.

40. Skrzypczak-Jankun E. Al-Senaidy A. Jankun J. Human Lipoxygenase: Structure, Function, Relevance to Human Diseases and Challenges in Drug Development. 4th International Conference on Drug Discovery and Therapy. Track: Hot Topics in Drug Targets (IL), Dubai, United Arab Emirates, February 12-15, 2012.

41. Skrzypczak-Jankun E. Eltaki N. Sabry D. Gohara A. Jankun J. Selman SH. Lysiak-Szydlowska W. Piotrowska M. Recombinant Lipoxygenase � a challenging target in human diseases, Zing Conference, Medicinal Chemistry Conference, Lanzarote, Spain, March 2-5, 2012.

Trent W. Nichols

Scientific Activities

Trent W. NicholsPhD

Pennsylvania Medical License
Maryland Medical License
Virginia Medical License
Address:USA
Biography

Trent W. Nichols Jr. M.D. is an internist, nutritionist, and ABIM gastroenterologist. He is the founder of the Center for Nutrition and Digestive Disorders and the Advanced Magnetic Research Institute in Hanover, Pennsylvania. A graduate of University of Denver with a BS in chemistry, and Northwestern University Medical School, he interned in the US Navy. His internal medicine/gastroenterology postgraduate work was also at Northwestern. He is a co-author of Optimal Digestive Health and has chapters in 3 textbooks. He has been involved in 41 pharmaceutical clinical trials. His research has been on fatty liver, mitochondrial defect as well as genetic preconditions to NASH and the �missing link, MTHFR gene defects,� to chronic illness. He recently concluded a study on pyridoxal 5�-phosphate deficiency. He is a member of the AGA, Bioelectromagnetic Society and Am. Neurogastroenterology Society and American College of Nutrition. He has been affiliated with Penn State Hershey, Hanover Hospital in PA and Wellspan in York PA. He is currently at Sinai Hospital in Baltimore MD. He is working now on a trial of muscadine seed extract in an obese mouse model of fatty liver.

Research Interests
Publications
Scientific Activities

Roberto P. Trevi�oPhD

Director
Social & Health Research Center
San Antonio
Address:USA
Biography

Roberto P. Trevi�o, M.D. founded the South Alamo Medical Group in 1986 for the practice of primary care medicine in poor and underserved areas. The medical practice has grown to five clinics and 20 physicians. Dissatisfied with medical outcomes, however, he founded the Social and Health Research Center (SHRC) in 1995 to design and evaluate early age obesity and type 2 diabetes school health prevention programs.

Dr. Trevi�o is the principal investigator of the two largest trials funded by the National Institutes of Health to prevent obesity and diabetes in children. Although these health programs have been shown to decrease blood glucose and obesity rates in children, Trevino presents in his new book- Forgotten Children- 10 years of evidence showing that politicians influenced by special interest group.

Research Interests

Blood glucose and obesity rates in children, primary care medicine in poor and underserved areas

Publications
Scientific Activities

Zaher MerhiPhD

Reproductive Endocrinology and Infertility
University of Vermont College of Medicine
Burlington, Vermont
Address:USA
Biography

Zaher Merhi has done Postdoctoral Fellow in Reproductive Endocrinology, Albert Einstein College of Medicine and Yeshiva University, Bronx NY and done his Clinical Fellow in Reproductive Endocrinology and Infertility, Albert Einstein College of Medicine and Yeshiva University, Bronx NY. Presently he is working as Assistant Professor, Reproductive Endocrinology and Infertility from University of Vermont College of Medicine, Burlington, Vermont from 2012.

Research Interests

Obstetrics and Gynecology Reproductive Endocrinology and Infertility

Publications
Scientific Activities

Yueshan HuPhD


Department of Psychiatry
Sanford School of Medicine University of South Dak
Address:USA
Biography

Dr. Yueshan Hu was a medical doctor of Integrated Traditional Chinese & Western Medicine in China, obtained his Ph.D. degree of Pharmaceutical Sciences in USA, and received his postdoctoral training in pharmacogenetics field. Currently, Dr. Hu works as a Research Scientist at Avera McKennan Hospital & University Health Center, and an Assistant Professor at University of South Dakota, Department of Psychiatry. With more than five senior-authored publications in obesity field, Dr. Hu was honored to be a Fellow of The Obesity Society.

Research Interests

Mechanisms, prevention, and treatment of metabolic disorders including obesity, diabetes, and hyperlipidemia,Pharmacogenetics,Phytomedicine

Publications
Scientific Activities

Deniz AtalayerPhD

St. Luke�s Hospital
Obesity Research and Nutrition Center
Columbia University
Address:USA
Biography

I completed my PhD in the Cognitive and Behavioral Neuroscience program at the University of Florida investigating obesity, energy homeostasis, and melanocortin system using animal models. I also have specific interest in neuroeconomics and decision making processes related to eating behavior. From there, I have switched to human neuroimaging in my postdoctoral fellowship at Columbia University/St. Luke's Hospital. I am currently using BOLD fMRI I to investigate gut-brain axis and the effects of bariatric surgery on the brain in obese individuals pre- vs. post-surgery.

Research Interests

Mechanisms, prevention, and treatment of metabolic disorders including obesity, diabetes, and hyperlipidemia,Pharmacogenetics,Phytomedicine

Publications
Scientific Activities

Jos� BellverPhD

AssociateProfessor
Reproductive Medicine Unit
University of Valencia
Address:Spain
Biography

Dr Bellver was born in Valencia, Spain, in 1969. He is a gynaecologist, specializing in reproductive medicine. He is currently a member of the Instituto Valenciano de Infertilidad, a university-affiliated infertility clinic in Valencia, Spain, and Associate Professor of the Department of Paediatrics, Obstetrics and Gynecology in the Faculty of Medicine of Valencia, Spain. He obtained his MD and PhD degrees with later Special Distinctions from the University of Valencia, in 1993 and 2001, respectively. In 1998 he was a Fellow of the High Risk Pregnancy Unit of the John Radcliffe Hospital, Oxford, UK. He is author or co-author of more than 160 publications and book chapters, co-editor of 6 books, member of the Editorial Board of four international medical journals, and reviewer of 19 journals related to gynaecology and reproduction. His special interests include mechanisms of recurrent miscarriage, impact of obesity on reproduction, prenatal diagnosis in assisted reproduction technologies (ART), and ART and chronic viral diseases.

Research Interests

His special interests include mechanisms of recurrent miscarriage, impact of obesity on reproduction, prenatal diagnosis in assisted reproduction technologies (ART), and ART and chronic viral diseases.

Publications
Scientific Activities

Jes�s Mill�n N��ez-Cort�sPhD

Professor
Universidad Complutense, Madrid
University of Valencia
Address:Spain
Biography

Undergraduate training in the School of Medicine of Universidad Complutense, with postgraduate training in Hospital Clinico de San Carlos, Madrid. Associate Professor of Internal Medicine in the University of Cadiz, and Full Professor in the same University and the University Complutense. Head of the Research group in �Molecular Basis of Atherosclerosis� in the University of Cadiz, and �Clinical Medicine and Atherosclerosis� in the Universidad Complutense of Madrid. Head of the Research group in �Molecular Basis of Atherosclerosis� in the University of Cadiz, and �Clinical Medicine and Atherosclerosis� in the Universidad Complutense of Madrid. Director of Teaching and Education Area, Agencia para la Formaci�n, Investigaci�n y Estudios Sanitarios, Community of Madrid, Spain. Head of Internal Medicine Department of the University Hospital Gregorio Mara��n in Madrid. Director of the University Hospital Gregorio Mara��n in Madrid. Research grants from: Fondo de Investigaciones Sanitarias, FEDER founds (EU), Comunidad de Andaluc�a, Comunidad de Madrid, Spanish Society of Internal Medicine, Spanish Foundation of Arteriosclerosis.

Research Interests
Publications
Scientific Activities

Jordi MerinoMD

Associated teacher
Biomedical Research Network in Diabetes and Associ
Universitat Rovira i Virgili
Address:Spain
Biography

Jordi Merino is Doctor in Nutrition and Metabolism by the Rovira i Virgili University (Spain). Actually, he works in the Vascular and Medicine Unit at Universitary Hospital Sant Joan de Reus, Spain. He is the responsible of the area of the therapeutic lifestyle outpatients clinic in this Unit and works in the CIBERDEM (Biomedical Research Network in Diabetes and Associated Metabolic Disorders ) platform. He is an associated teacher of the Rovira i Virgili University of the degree in Nutrition and Dietetics.

Research Interests

His main clinical research is focused on the effects of therapeutic lifestyle changes (diet, smoking and physical activity) on small artery endothelial function in patients at increased cardiovascular risk, especially obesity, type 2 diabetes and metabolic syndrome. Recently and regarding this topic, he has published several papers in national and international peer review journals. His last publication, in the Menopause Journal, shows the effect of low intensity physical activity on small artery endothelial function, body fat distribution and inflammation.

Publications
Scientific Activities

Jos� Javier Mart�n-RamiroPhD

Associate Professor
Obesity unit department of surgery
Alfonso X el sabio University Rey Juan Carlos Univ
Address:Spain
Biography

Dr Mart�n-Ramiro is MD by the School of Medicine, Universidad Aut�noma Madrid (Spain), and he completed his PhD in the Preventive Medicine program at the Rey Juan Carlos University, investigating obesity and burden of disease attributable.

He is the obesity unit responsable at the Surgery Deparment of Severo Ochoa Hospital and the bariatric surgery program. Also he is the responsable of the training surgeons program at his hospital.

He is autor or co-author of more tan 70 publications and book chapters, and member of spanish surgeons association, bariatric surgeons association and quality care section.

Research Interests

Cost of illness, burden of disease and economics consequences derived from obesity and overweight. He is currently the head of the research group in psychiatrics consequences pre-vs postbariatric surgery.

Publications
Scientific Activities

Kristine F�rchPhD


Clinical Epidemiology
Steno Diabetes Center
Address:Denmark
Biography

Kristine F�rch graduated in 2004 from the Institute of Human Nutrition, University of Copenhagen, and attained her PhD in 2009 from the Faculty of Health Sciences, University of Copenhagen. Kristine F�rch works as a Senior Researcher in the department of Clinical Epidemiology at Steno Diabetes Center and is also involved in educational programmes targeting medical doctors at specialist level in China, India and the Middle-East.

Research Interests

Kristine F�rch�s research focuses on the heterogeneity of type 2 diabetes with special emphasis on the pre-diabetic conditions impaired fasting glycaemia and impaired glucose tolerance. By using large-scale epidemiological studies as well as smaller detailed metabolic studies, she studies the pathophysiological mechanisms driving fasting and 2-hour post-load hyperglycaemia. Particularly, she is interested in the relationship between insulin resistance and beta cell dysfunction, the impact of incretin hormones, and the role of obesity in the development of type 2 diabetes. The overall scope of her research is to identify subgroups in need for specialised prevention and treatment of type 2 diabetes and cardiovascular disease.

Publications
Scientific Activities

Emad KandilPhD

Associate Professor of Surgery

Tulane University School of Medicine
Address:USA
Biography

Schlieder Chair in Surgical Oncology and the Chief of Endocrien Surgery sections at Tulane University Medical School, New Orleans, LA. He completed his training with a clinical fellowship in endocrine surgery at Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Kandil is a fellow of American College of Surgeons and full-time academic faculty at Tulane University School of Medicine. He has written more than 100 original articles, invited reviews and book chapters and served on numerous editorial boards.

Research Interests

His research interests have focused on clinical outcome research related to thyroid and parathyroid patients.

His laboratory research focus examining the anti-tumor efficacies of multiple pathways targeting in advanced thyroid cancer.

Publications
Scientific Activities

Nora L. NockPhD

Genetic Epidemiology and Bioinformatics
Department of Epidemiology and Biostatistics
Case Western Reserve University
Address:USA
Biography

Dr. Nock is an Assistant Professor in the Department of Epidemiology and Biostatistics at Case Western Reserve University (CWRU). She also holds an appointment in the Department of Pathobiology at the Cleveland Clinic. Dr. Nock has a background in engineering and epidemiology and has received additional training in neuroimaging (functional MRI) methods.

Research Interests

Dr. Nock's research interests include better understanding the genetic, environmental and neuro-behavioral determinants of obesity and cancer and improving cancer survivorship through lifestyle interventions.

Publications
Scientific Activities

Antonio Arnaiz-VillenaPhD

Head of Immunology
Microbiology Department
University Complutense
Address:Spain
Biography

Antonio Arnaiz Villena is presently Head of Immunology and Microbiology I Department at University Complutense and Hospital 12 de Octubre in Madrid, Spain. He was born and studied Biology and Medicine in Madrid. He accomplished post-doctoral research during 9 years in the UK at the Middlesex Hospital Medical School (Prof Roitt) and at the London Hospital Medical College (Prof Festenstein). He came back to Spain and set up Immunology and Genetics laboratories in the Spanish National Health Service in Madrid (Hospital Ramon y Cajal, The Madrid Regional Blood Center and Hospital 12 de Octubre). He was also appointed in Madrid Full Professor of Immunology by an International Board, including Pablo Rubinstein and Antonio Coutinho. He has established Immunology teaching at Biochemistry, Medicine, Biology, Pharmacology, Veterinary Faculties at University Complutense, Madrid. He has served 5 years as elected President of the Spanish Society for Immunology and 14 years in the Government Spanish Board for Specialists. He has published 341 papers in international magazines, published 8 books and directed 48 PhD Doctoral Theses in Immunology, Obesity, Human and Bird Population Genetics and Linguistics.

Research Interests
Publications
Scientific Activities

Manoj SharmaPhD

Professor
Health Promotion & Education
University of Cincinnati
Address:USA
Biography

Manoj Sharma, MBBS, MCHES, Ph.D., is a professor in the Health Promotion and Education program and Department of Environmental Health at the University of Cincinnati. He is a physician by initial training and has also completed his doctorate in Preventive Medicine/Public Health from The Ohio State University.He has worked in Community Health designing and evaluating health education programs for more than 25 years at all levels: local (Columbus Health Department, Omaha Healthy Start Program, Lead Safe Omaha Coalition); state (Nebraska Health & Human Services, Ohio Commission on Minority Health, Ohio Department of Health); national (American School Health Association, National Commission for Health Education Credentialing); and international (India, Italy, Mongolia, Nepal, United Arab Emirates, Vietnam).

Research Interests

His research interests are in designing and evaluating theory-based health education and health promotion programs, childhood obesity, alternative and complementary systems of health, and community-based participatory research.

Publications
Scientific Activities

Virginia KaklamaniPhD

Associate Professor
Division Hematology/Oncology
Northwestern University
Address:
Biography

Dr Kaklamani is an Associate Professor in the Division of Hematology/Oncology at Northwestern University. She completed her medical training with honors at the University of Athens and her residency in Internal Medicine at Newton-Wellesley Hospital in Boston, MA. Dr Kaklamani completed her fellowship in hematology/oncology at Northwestern University in June of 2003. She also received a Master of Science in Clinical Investigation from Northwestern University in June of 2003. Her research interests include studying high risk families and the role of exercise and diet in breast cancer.Dr Kaklamani joined the faculty of the Division of Hematology/Oncology at Northwestern University in July of 2003 upon completing her fellowship. She is board certified in Medical Oncology.

Research Interests

Dr Kaklamani�s clinical interest is breast cancer and cancer genetics.

Publications
Scientific Activities

Zhong Q WangPhD

Associate Professor
Pennington Biomedical Research Center
Louisiana State University Systems
Address:USA
Biography

Dr. Zhong Q Wang is a research assistant professor of Pennington Biomedical Research Center, LSU systems, in Baton Rouge, U.S.A. He has obtained his M.D at Shanghai Medical University in Shanghai in 1986. Dr. Wang has more than 20 years experience in the field of studying obesity and diabetes. He also investigates the effects of nutritional interventions on cellular signaling pathways as well as mitochondrial function. He has a broad background in molecular biology, with specific training and expertise in key research areas. He expanded his research to focus on the effect of chromium on insulin signaling in obese JCR rats. Later, he investigated the gene profiles of muscle tissue in caloric restricted monkeys and demonstrated that caloric restriction significantly reduced ubiquitin-proteasome gene expression. He studied sugar cane fiber as a dietary supplementation in high fat-diet fed mice and showed sugar cane fiber dramatically reduced plasma leptin and insulin concentrations and prevented diet-induced obesity. Dr. Wang demonstrated that adenovirus type 36 (Ad-36), a virus induced obesity by increasing glucose uptake via up-regulation of the PI 3K-Ras pathway and increased GLUT4 expression independent of insulin signaling in cultured human skeletal muscle cells. He also reported that Ad-36 reduces fatty acid oxidation by increasing Cidec/FSP27 expression in cultured human muscle cells. He has published over 40 papers and serves as peer reviewer for 10 medical journals.

Research Interests

He has broad research interesting including dietary fiber supplementation, relationship between nutrition and chronic diseases, trace element- chromium study, cellular signaling, caloric restriction, aging, adenovirus type 36-induced obesity, diabetes and metabolic syndrome.

Publications
Scientific Activities

Christopher Nicholas OchnerPhD


Director of Research Development and Administratio
Icahn Scool of Medicine at Mount Sinai
Address:USA
Biography

Dr. Christopher Nicholas Ochner is recently transferring his independent research laboratory from the Columbia University College of Physicians & Surgeons to the Icahn School of Medicine at Mount Sinai, Dr. Christopher Ochner conducts cutting-edge research on nutrition and the brain. With a Ph.D. in clinical psychology, he also serves as a Research Associate at the New York Obesity Nutrition Research Center. Dr. Ochner completed a research internship at the National Institutes of Health, a clinical internship at the University of Maryland School of Medicine, and a fellowship at the Columbia University Institute of Human Nutrition.

Research Interests

Dr. Ochner has devoted his career to studying the relation between food intake and the brain, receiving multiple awards from the National Institutes of Health, Columbia University, Mount Sinai and New York Obesity Nutrition Research Center to support his research. He has published more than twenty peer-reviewed scientific articles relating diet and nutrition, made numerous media appearances, and lectures around the world.

Publications
Scientific Activities

Joaquin P�rez-GuisadoPhD


Plastic surgeon and Physician specialist in weight
Estepona
Address:Spain
Biography

Dr. Joaqu�n P�rez-Guisado Rosa studied Veterinary (2000) at the University of C�rdoba (Spain) and Human Medicine and Surgery (2004) at the University of Granada (Spain). He got the PhD in Veterinary (2004) at the University of C�rdoba (Spain). He was the Medical Director (2005-2008) at a pharmaceutical laboratory (Laboratorios P�rez Gim�nez., C�rdoba, Spain). He got 4 certifcates on National Personal Trainer of Bodybuilding and Fitness (2002, Spanish Association of Bodybuiliding and Fitness, AEF)), Homeopathy (2006, Homeopathy institute of Catalu�a, Spain), Phytotherapy (2006, Spanish Association for Continuing Education in Health Sciences and Education, Ja�n, Spain) and Animal Experimentation (2008, Junta de Andaluc�a, Spain). He has 2 Master Degrees: in Sport Medicine (2006, Spanish Association for Continuing Education in Health Sciences and Education, Ja�n, Spain) and Pharmacovigilance and Postauthorization studies (2007, University of Sevilla , Spain). He finished the Medical Specialty of Reconstructive, Plastic and Aesthetic Surgery (2013) at the University Hospital of Reina Sofia (C�rdoba, Spain). He discovered and published the weight loss program internationally known as �Ketogenic Mediterranean diet�. He has published 40 Scientific articles, 29 Scientific communications and has been Guest Speaker 2 times. He is member of the editorial board of the international journal "International Journal of Burns and Trauma". Actually he is finishing his PhD in Nutrition and Metabolism (University of Cordoba, Spain), he is Honorary Collaborative Professor at the Genetic Department at the University of Cordoba (Spain) and is working as a Plastic surgeon and Physician specialist in weight loss at Hospital of Hospiten, Estepona, M�laga (Spain).

Research Interests

Nutrition and Metabolism, Weight loss, Sport Medicine, Pharmacology and Plastic, Reconstructive and Aesthetic Surgery.

Publications
Scientific Activities

Tomo YonezawaPhD

Assistant Professor

Tokyo University of Science
Address:Japan
Biography

Tomo Yonezawa, received his PhD from Department of Animal Physiology, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan during 2004-2007. He completed his Master degree in agriculture as specialization from Department of Animal Physiology, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan. He has submitted his thesis on Screening of fatty acids-induced novel functional genes in mammary epithelial cells. He has published more than 30 papers and given many good presentations. He worked as Research Assistant Professor from Department of Systems BioMedicine, Tokyo Medical and Dental University, Japan. Currently, he is working as Assistant Professor from Research Institute for Biomedical Sciences, Tokyo University of Science. He is engage in examining the phenotype of Knock-out mice using Collagen-induced arthritis, or Experimental autoimmune encephalomyelitis. He is the member of the Japanese Society of Animal Science, Member of The Molecular Biology Society of Japan and also The Japanese Society for Immunology.

Research Interests

The molecular mechanism of pathogenesis for metabolic and autoimmune disorders, especially linking relationships between metabolic disorder and chronic low-grade inflammatory condition. His main career is of examining the phenotype of DCIR-deficient mice, which is spontaneously shown to have symptoms resembling auto immune diseases such as Rheumatoid arthritis, Sj�gren's syndrome.

Publications
Scientific Activities

Nicolini AntonelloMD




Address:ITALY
Biography

I lead a Respiratory Rehabilitation Unit and ALS (amyotrophic lateral sclerosis) CENTER ,Hospital of Sestri Levante – Italy

Research Interests

My research interest is in NON INVASIVE VENTILATION – SLEEP BREATHING RELATED DISORDERS and OBESITY HYPOVENTILATION SYNDROME – PULMONARY REHABILITATION

Publications
Scientific Activities

D NarangMD

Assistant Professor
Anaesthesiology
Maharishi Markendeshwar College of Medical Sciences & Research
Address:India
Biography

Dr Deepak Narang, M.D. Anesthesiology is presently working as Assistant Professor Anesthesiology at Maharishi Markendeshwar College of Medical Sciences & Research.He did his graduation and postgraduation from Pt. B.D.S. postgraduate institute of medical sciences,Rohtak,India.After that he joined 3 year senior residency program at Dept. of Anaesthesiology & Critical care, All India Institute of Medical Sciences, New Delhi,India.He also did a fellowship in Clinical Anesthesia from Dept. Of Anesthesiology,University of Toronto, Canada.Dr Narang has number of publications in various international and national journals of repute.He has also presented his research work in various international conferences.He is reviewer for Archives of International Surgery journal.

Research Interests

Obesity,Geriatric Anesthesia,Obstetric anesthesia, Regional anesthesia and Pain Management.

Publications
Scientific Activities

Peter D. HartPhD

Associate Professor
College of Education, Arts & Sciences, and Nursing
Montana State University-Northern
Address:Havre
Biography

Dr. Hart is an Associate Professor in Health Promotion at Montana State University – Northern. Dr. Hart completed a PhD in Human Performance emphasizing Kinesmetrics at Middle Tennessee State University. He is trained in quantitative research methods including epidemiology, applied statistics, and measurement & evaluation. Dr. Hart’s research interests are in applied health promotion programming, measurement issues related to health assessments, secondary data & meta-analyses, and population health

Research Interests

Assessment in Health Education
Kinesiology & Biomechanics
Theory & Practice in Community Health Education
Exercise Physiology
Sport & Exercise Nutrition
Community Health
Health Promotion Implementation & Assessment

Publications
Scientific Activities

Maciste H Macias-CervantesPhD


Medical Science Department
Universidad de Guanajuato
Address:León Guanajuato Mx
Biography

Dr Maciste H Macias obtained his MD at the School of Medicine, Universidad de Guanajuato (México), he completed his PhD at Medical Science program at the Departamento de Ciencias Médicas Universidad de Guanajuato (Mexico), investigating the effect of physical activity upon insulina resistance in children. Currently he is the coordinator in Master in Medical Science program of the Medical Science Deparment of Universidad de Guanajuato (Mexico) He is at present seeking to better understand molecular pathways about exercise training in obese adolecsents, in order to prescribe better options of exercise in metabolic diseases.

Research Interests

His main clinical research has been focused on the effects of physical activity and diet on skeletal muscle molecular pathways in obese patients, type 2 diabetes and metabolic syndrome. He has published several papers in national and international peer review journals.

Publications
Scientific Activities

KAMILE KUKUlu

Associate Professor
School of Health
Akdeniz University
Address:Turkey
Biography

Kamile KUKULU is professor Nursing Faculty, Akdeniz University. She has been working related to psychosomatic obstetrics and gynecology, women’s health, community-based care services for elderly people, ergotherapy for elderly people, and immigrant families. She conducted the project of training unemployment elderly care workers and nurses to act as a caregiver in home care centres for elderly people in Turkey. This project is supported by EU in 2011.

Research Interests
Publications
Scientific Activities

Francisco Mendoza CarreraPhD

Associate researcher
Western Biomedical Research Center
Instituto Mexicano del Seguro Social
Address:Mexico
Biography

Francisco Mendoza Carrera was graduated as chemical-pharmaceutical-biologist in 1999; obtained his degrees of Master and Doctor in Human Genetics in 2003 and 2005, respectively, all at the University of Guadalajara, in Mexico. He was fellow of the Mexican National Council of Science and Technology (CONACyT) and the Mexican Social Security Institute (IMSS) during their graduate studies. He is currently affiliated as Associated Researcher at the department of Molecular Medicine of the Western Biomedical Research Center of the IMSS. He has been Professor of Molecular Biology and Assistant Professor of Population Genetics at the University of Guadalajara. Dr. Mendoza-Carrera has been involved in several studies about the genetic variability in the inflammatory response and oxidative stress in different physiological conditions such as metabolic syndrome, renal transplantation and autoimmunity. He has also done studies of genetic diversity based on HLA region in the Mexican population.

Research Interests

1. Inflammation genetic polymorphisms in adolescents with metabolic syndrome findings.
2. Analysis of the influence of polymorphisms inflammation response genes on the progress of the diabetic nephropathy, dialysis and renal transplantation.
3. Allele and haplotype diversity analysis of the HLA locus in Mestizo and Native populations of Mexico.

Publications
Scientific Activities

Grief samulePhD

Associate Professor
Department. Of Family Medicine
University of Illinois
Address:Chicago, IL 60612-7248
Biography

board-certified family physician for 22 years. A graduate of McGill University in Montreal, Canada, Dr. Grief has worked in private practice, urgent care and academic family medicine. His primary interests are in obesity and endocrinology, particularly diabetes management. His most current interest is lifestyle modification and motivational interviewing, with an emphasis on promoting wellness.
Dr. Grief is co-author of “The End of Obesity”, a self-help book for patients. He has also authored many articles pertaining to preventive health care. He has given numerous presentations on the gamut of primary care-related topics for a variety of organizations. He has lectured for local, regional and national audiences under the auspices of the Illinois Academy of Family Physicians, the American Medical Association, and the Society of Teachers in Family Medicine.
Dr. Grief was named one of Chicago’s Top Doctors in 2012 by Chicago magazine and in 2013 one of America’s Top Doctors by Castle and Connolly.

Research Interests

obesity, diabetes, nutrition.

Publications
Scientific Activities